Corticosteroids plus rhTPO versus corticosteroid monotherapy as initial therapy in elderly patients with newly diagnosed primary immune thrombocytopenia: a propensity score-matched real-world study
This propensity score-matched real-world study demonstrates that adding recombinant human thrombopoietin (rhTPO) to frontline corticosteroids significantly improves initial response, complete remission, and sustained response rates in elderly patients with newly diagnosed primary immune thrombocytopenia compared to corticosteroid monotherapy, while maintaining a comparable safety profile.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Immune thrombocytopenia is a condition where the body's own defense system mistakenly attacks and destroys its platelets, the tiny cell fragments responsible for stopping bleeding. For most people, this results in easy bruising or minor bleeding, but for older adults, the stakes are much higher. As people age, their bodies become less able to handle the side effects of the standard treatment: powerful anti-inflammatory drugs called corticosteroids. While these drugs can calm the immune system and stop the platelet destruction, they often cause severe problems in elderly patients, such as dangerously high blood sugar, high blood pressure, and infections. Furthermore, the relief these drugs provide is frequently temporary; once the medication stops, the platelet count often drops again, leaving the patient vulnerable. Doctors have long sought a way to boost platelet production directly, using a natural hormone called thrombopoietin, which acts as a signal for the bone marrow to make more platelets. The question facing clinicians has been whether adding this hormone to the standard steroid treatment could offer older patients a faster, longer-lasting recovery without increasing the risk of harm.
Researchers from ten hospitals across China set out to answer this question by looking back at the medical records of elderly patients who had just been diagnosed with the condition. They focused on two groups of patients: those who received only the standard steroid treatment and those who received the steroids combined with a synthetic version of the thrombopoietin hormone. To ensure a fair comparison, the team carefully matched patients from both groups based on their age, sex, existing health conditions like heart disease or diabetes, and how severe their bleeding was at the start. This process, known as propensity score matching, allowed them to isolate the effect of the added hormone from other factors that might influence the outcome. The study included 124 patients in total, with 62 in each group, all of whom were treated between 2017 and 2024.
The results showed a clear advantage for the combination therapy. Patients who received the hormone alongside the steroids were significantly more likely to achieve a rapid and complete recovery of their platelet counts compared to those who received steroids alone. Specifically, about 60 percent of the combination group reached a full remission, where their platelet counts returned to normal levels without any bleeding, whereas only about 35 percent of the steroid-only group achieved this same result. The benefit extended beyond just the initial recovery. Patients in the combination group were more likely to maintain these healthy platelet levels for at least six months without needing further treatment. The data also indicated that the combination therapy led to higher peak platelet counts, suggesting a more robust response from the bone marrow. While the time it took to see the first improvement was similar in both groups, the durability of the recovery was markedly better when the hormone was included.
Safety was a primary concern, given the vulnerability of the elderly population. The study found that the combination therapy did not lead to a higher rate of general side effects compared to steroids alone. In fact, there were trends suggesting fewer steroid-related issues, such as weight gain, sleeplessness, and new-onset high blood sugar, in the group that received the hormone. This likely occurred because the added hormone helped the body recover faster, allowing doctors to reduce the steroid dose sooner. However, the researchers did note a small, non-statistical increase in blood clot events in the combination group. These clots occurred primarily in patients who already had a history of heart or blood vessel disease, highlighting the need for careful monitoring in those with pre-existing vascular risks. One patient in the combination group died from a brain hemorrhage, and one in the steroid-only group died from a severe lung infection, underscoring that the disease itself remains dangerous regardless of the treatment path.
Ultimately, the study suggests that adding a synthetic thrombopoietin hormone to the initial steroid treatment offers a more effective and durable path to recovery for older adults with this blood disorder. The combination appears to help the body rebuild its platelet supply more effectively while potentially sparing patients from the cumulative toll of long-term steroid use. While the findings are promising, the researchers emphasize that these results come from a retrospective review of past cases, and future randomized trials are needed to confirm the safety profile, particularly regarding blood clots, and to establish the best way to use this combination in routine care. For now, the evidence points toward a strategy that could help elderly patients achieve a stable recovery with fewer long-term complications.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.